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Background/aim: PARV4, a small DNA virus belonging to the family Parvoviridae, was first isolated in an HBV injecting drug user.
Several studies have investigated PARV4 co-infection with HBV and HCV and its effect on the progression of liver disease. The aim of
this study was to determine the frequency of PARV4 among HBV-infected patients and healthy individuals.
Materials and methods: A group of 90 HBV patients and a group of 90 healthy subjects were included in this study. Samples were
selected after screening tests such as HBsAg ELISA, anti-HCV ELISA, and anti-HIV ELISA. Nested-PCRs were conducted to detect the
PARV4 genome. Positive samples were then subjected to DNA sequencing.
Results: PARV4 DNA was detected in 4.4% of HBV patients in comparison with 1.1% of healthy individuals (P-value: 0.36). DNA
sequencing results revealed that PARV4 in all five positive samples was genotype I.
Conclusions: Although this pilot study showed no significant difference between the frequency of PARV4 among HBV patients and
healthy donors, further studies with a larger sample size are suggested to determine the association of PARV4 with HBV co-infection
and the impact of this virus on the progression of liver disease in patients with hepatitis B.
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1. Introduction
Human parvovirus 4 (PARV4) genotype I was first
identified in 2005 in plasma from a homeless, intravenous
drug user simultaneously infected with hepatitis B virus
(HBV) and showing symptoms of an acute viral infection
that included fatigue, nausea, diarrhea, sore throat,
and joint pain (1). Genotypes II and III were identified
in 2006 and 2008, respectively (2,3). The nucleotide
difference between genotypes I and II is about 8% in
sequenced regions (3,4). Two large nonoverlapping open
reading frames, ORF1 and ORF2, organized the genome
of PARV4 and encode respectively a nonstructural and a
capsid protein (5). Initially it was suggested that this virus
is transmitted only through parenteral routes because
it is more common in people who have been exposed to
blood. It had been detected in hemophiliacs that received
nonvirally inactivated clotting factors (5–8). However, a
study in Africa detected PARV4 DNA in nasal and fecal
samples; thus respiratory and fecal–oral transmission of
the virus was suggested (9). Nonparenteral transmission
has also been reported in South Africa and India (10,11).
In addition, researchers that conducted a study in Taiwan
* Correspondence: agorzin@gmail.com
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suggested placental transmission (12). So far, the virus has
been isolated from many tissues including bone marrow
of HIV-positive individuals (13) and the liver of HBVand HCV-infected patients (14,15). Moreover, the virus
has been diagnosed in plasma, cerebrospinal fluid (CSF),
skin, myocardium, and blood products around the world
(1,3,7,8,11,15–17). Despite the detection of viral nucleic
acid in many organs, PARV4 has scarcely been linked
to specific symptoms, except for a recent study that was
conducted in Africa linking PARV4 to encephalitis (11)
and another study in which the virus was diagnosed in
people with symptoms including pharyngitis, nausea,
and joint pain (1). However, it is difficult to determine
a pathological association because PARV4 was often
found in individuals with HCV, HBV, or HIV infection.
Nevertheless, as a common co-infection with these
pathogens, PARV4 may have an important role in clinical
disease because of recent experiments that are indicative
of an immune response to the virus (18,19). In spite of the
short duration of viremia, the virus is detectable for a long
time in the tissue, causing a latent infection with PARV4
(13,14,20). In the present study, considering the results
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of previous studies that indicate a significant association
between B19 and hepatitis B and C viruses (21,22), and also
according to the possibility of PARV4 related with these
viruses, we compared the prevalence of PARV4 viremia
in healthy subjects and HBV-infected individuals and
determined its genotype in positive cases.
2. Materials and methods
2.1. Sample collection
We altogether analyzed 180 samples in two groups. The first
group consisted of 90 cases in patients with hepatitis B who
were not co-infected with HCV or HIV. These samples were
consecutively collected during a 5-month period (October
2012–January 2013) from patients referred to Motahari
Clinic in Namazi Hospital, Shiraz. Sampling was carried
out by professionals with written informed consent of
patients. The second group (control) consisted of 90 samples
from healthy individuals that were collected from staff and
students of Shiraz University of Medical Sciences and they
tested negative for HBs Ag.
In the HBV-infected group women formed 25.5% of
patients (23/90), with a mean age of 42 years, and men
consisted 74.5% (67/90) of patients, with an average age
of 47 years. Other information regarding the participants
in this group is as follows: 10 healthy carriers of hepatitis
requiring no treatment, 2 patients with liver cirrhosis caused
by hepatitis B virus who were on the waiting list for a liver
transplant, 20 patients who received a liver transplant due to
liver cirrhosis caused by HBV, and 54 subjects with chronic
hepatitis B receiving treatment with Tenofovir. Figure 1
shows the status of hepatitis B in members of this group.
In the healthy group 26.6% (24/90) were women, with a
mean age of 40 years, and 73.4% (66/90) were men, with a
mean age of 43 years.

2.2. Screening tests
Anti-HCV Ab and anti-HIV Ab were the first tests done
on all samples using ELISA kits (Pishtaztb, Tehran, Iran).
Positive samples were excluded from our study and
negative samples were examined by HBsAg test using an
ELISA kit (Pishtazteb, Tehran, Iran). Based on the positive
or negative results, subjects were divided into two distinct
groups. After that, nucleic acid was extracted from all 180
samples (using Cinnapure Viral kit); then HBV-PCR was
performed on samples that tested positive for HBsAg that
gave approval for hepatitis B (using Cinnagen kit, Tehran,
Iran).
2.3. PARV4 DNA detection
The DH5α strain of E.coli was transformed by a plasmid
containing the genome of PARV4 genotype I (GenBank:
AY622943.1) by electroporation. The transformed bacteria
were cultured in LB medium containing ampicillin (50
µg/mL). Afterwards, nucleic acid was extracted and used
as a positive control to set up PARV4 nested-PCR. PCR
was performed using specific primers (16) targeting the
first open reading frame (ORF1) (Table 1). Time and
temperature for both the PCR steps were similar and
as follows: 96 °C for 9 min, followed by 45 cycles of 96
°C for 30 s, 55 °C for 30 s, 72 °C for 1 min, and a final
extension of 7 min at 72 °C (16). In the first round 5 µL
of extracted nucleic acid was used in a final volume of 50
µL and subsequently 5 µL of the first round PCR product
was used as a template for the second round amplification.
The final PCR product was analyzed on 1% agarose gel
electrophoresis. The PCR products of the positive samples
were purified from the gel using a DNA extraction kit
(Bioneer Co., South Korea) and were then sequenced
using internal primers.

Figure 1. HBV patients according to disease status. *HCC: Hepatocellular carcinoma.
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Table 1. Primers used in this study to detect PARV4.
Primer name

Primer sequence

PV4NS1F

5´-AAGACTACATACCTACCTGTG-3´

PV4NS1R

5´-TGCCTTTCATATTCAGTTCC-3´

PV4NS1Fn2

5´-GTTGATGGYCCTGTGGTTAG-3´

PV4NS1Rn2

5´-CCTTTCATATTTCAGTTCCTGTTCAC-3´

3. Results
To specify groups, initially all samples were tested for
HBsAg by ELISA, the results of which were negative.
Another test performed on all samples was anti-HCV Ab
ELISA, the results of which were also negative.
The lack of correlation between PARV4 and HBV coinfection: One sample of 90 subjects in the control group
(1.1%) that belonged to a 40-year-old man and 4 samples
out of 90 (4.4%) in HBV patients were positive for PARV4
DNA. Statistical analysis (using Fisher’s exact test) showed
no significant difference between the two groups (P-value
= 0.36). Figure 2 shows the PARV4 nested-PCR results (a
168 bp band) for five positive samples along with negative
and positive controls.
Positive samples of HBV-infected subjects included
a healthy carrier female (10% of carriers) and 3 males, 2
patients with chronic hepatitis B (3.7% of patients with
chronic hepatitis B) and 1 who received liver transplant
due to liver cirrhosis caused by HBV (4.5% of cirrhotic
patients). Table 2 show details of the 5 PARV-infected
persons in this study. Sequencing results revealed that
the virus in the 5 positive cases was PARV4 genotype I
(Figure 3). The sequence was submitted to GenBank and is
accessible under KP216530.
4. Discussion
Previous studies have shown an important association
between HBV and B19; and also PARV4 was first

identified in an HBV-infected person. In the present
study to determine the possible association between
PARV4 and HBV co-infection we examined the PARV4
viremia in healthy subjects and HBV-infected individuals.
In addition, we specified the genotype of PARV4 in our
positive samples.
A similar study was conducted in 2013 in north China
and reported the same molecular abundance of PARV4
in both healthy subjects and patients with hepatitis B.
Altogether, 1626 blood samples from healthy individuals
and HBV patients were collected and DNA from three
human parvoviruses, B19, Bocavirus (HBoV) and PARV4,
was detected. Of all blood samples tested, 138 (8.49%)
were found to exhibit HPAV (human parvoviruses)
viremia, including 3.51% with B19, 3.75% with HBoV, and
2.52% with PARV4 although no significant correlation
between HBV and HPAV including PARV4 was found
(23). These results correspond to those observed in our
study. However, other studies have reported different
results in comparison to our study. A study in 2012
characterized the association of PARV4 with HBV and
HCV infection in Shanghai (24). Sera from 51 out of
153 (33.3%) of HCV-infected subjects compared to only
16.7% (16/96) matched controls were positive for PARV4
DNA (P = 0.004). Similarly, PARV4 DNA detection was
significantly higher in HBV-infected individuals (41.5%,
78/188) compared with the control group (P < 0.0001).
However, in that study, the measurement of ALT (alanine
aminotransferase) level showed that PARV4 does not have
any effect on the severity of HBV disease. In our study,
ALT level in the 2 patients with chronic hepatitis B, coinfected with PARV4, was higher than the HBV chronic
Table 2. Demographic information of PARV4-infected subjects.

Figure 2. PARV-PCR results. From left to right are marker,
negative control, positive control, and five positive samples.
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No.

Hepatitis B status

Sex

Age

ALT (U/L)

1

healthy

male

40

12

2

healthy carrier

female

31

10

3

chronic hepatitis

male

24

62

4

chronic hepatitis

male

34

46

5

liver cirrhosis

male

86

13
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Figure 3. A representative of sequence alignment. One of our positive samples (GenBank: KP216530.1) is aligned against the
positive control (GenBank: AY622943.1).

infected patients who were not positive for PARV4 DNA.
However, statistical analysis on the liver enzymes required
larger groups. In another study in 2007 in London, PARV4
DNA frequency was reported in 30% of the blood samples
(3 out of 10) from cadavers of injecting drug users who
were also infected with HCV (25). A study in the United
Kingdom in 2007 detected PARV4 DNA from 70% (17/24)
of bone marrow, lymphoid tissues, and brains of HIVinfected persons, but plasma samples of these patients were
negative for PARV4. Presence of PARV4 DNA in tissues in
the absence of viremia suggests that persistent infection
with the virus in tissue occurs more than acute infection.
PARV4 DNA sequencing showed a significant difference in
HIV-infected individuals in age between those that carried
PARV4 genotype I and those infected with genotype II. As
all people infected with genotype I were born in 1968 or
later, they were 38 years old or less. This result is similar
to the results obtained in our study. Samples infected with
genotype II in the mentioned study belong to the natives
in 1956 and later (13). In 2011, Touinssi et al. detected
PARV4 DNA in 27.3% (6 out of 22) of HCV-infected
individuals and 38.7% (29 out of 75) of HBV patients (26).

It is thought that the high prevalence of PARV4 viremia
in HIV-, HCV-, and HBV-infected subjects may actually
reveal a commonly higher exposure to infectious agents in
these groups (24). Regarding the immune response to the
virus and since viral antigens express on lymphoid tissue
and liver cells, it suggests that PARV4 may affect HBV,
HCV, and HIV pathogenesis (13,14).
Prior to 2007, PARV4 was not isolated from tissues of
individuals without HIV infection but in this year a study
was done on the livers of 87 non-HIV-infected persons
and samples from 13 of them (15%) were positive for the
presence of PARV4 DNA (14). The results of that study
showed that PARV4 can cause a persistent infection in
the tissue like B19 does. All specimens examined, except
one, were derived from those who were not infected
with HIV. In addition none, except one, had a history of
intravenous drug use. The samples from both individuals
tested negative for PARV4 DNA. These findings imply that
infection with this new member of the family Parvoviridae
is not restricted to HIV-infected subjects. PARV4 detection
of blood donor samples also confirms this theory (16).
Briefly this study demonstrates the presence of PARV4
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in the liver of a wide range of people, although further
studies are needed to clarify the importance of the stability
of the virus and its impact on liver disease. Note that the
sequencing results of this study showed that all samples
infected with genotype I belonged to those aged between
56 and 64 years and all samples infected with genotype II
were from those aged between 64 and 85 years. The results
of our study showed infection with PARV4 genotype I in
those aged 25 to 40 years except for one sample from an
86-year-old male. The difference in distribution of PARV4
in relation to the region can be justified by the following
parameters including the epidemiology of PARV4 and the
study population.
Our study has some shortcomings including small
sample size and not separating hepatitis B clinical
presentation such as inactive carrier, chronic active, and
HBe Ag positive.
In conclusion, this is the first study on PARV4 in
Iran and our data showed infection with this virus in this

country. Future studies are recommended to investigate
the abundance of PARV4 in different regions in Iran;
frequency of different genotypes; routes of transmission;
impact of the virus in co-infection with viruses such as
HBV, HCV, and HIV; pathogenesis; etc. It is also suggested
to examine the presence of PARV4 DNA in the liver of
people who have liver manifestation of unknown etiology.
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